INBIOGEN CO (101140) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, INBIOGEN CO (101140) reported revenue of 6.3 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
20256.3 billion KRW-4.3 billion KRW-1.4 billion KRW[source]
20247.0 billion KRW-6.1 billion KRW16.1 billion KRW[source]
20236.2 billion KRW-6.2 billion KRW11.3 billion KRW[source]
202211.4 billion KRW-6.3 billion KRW-117.2 billion KRW[source]
202110.5 billion KRW-7.9 billion KRW94.1 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025160.0 billion KRW2.3 billion KRW157.6 billion KRW[source]
2024162.7 billion KRW2.9 billion KRW159.8 billion KRW[source]
2023145.7 billion KRW2.6 billion KRW143.1 billion KRW[source]
2022144.3 billion KRW37.4 billion KRW106.9 billion KRW[source]
2021274.5 billion KRW96.5 billion KRW178.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice